Biotechnology
Clarivate Introduces Epidemiology Intelligence™ for Precision Patient Population Analysis
Empowering biopharma with unified epidemiology, incidence and prevalence data alongside claims-based population insights, for precise market sizing and patient population analysis LONDON, May 7, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intellig...
GC Genome to Present New Clinical Data on Colorectal Cancer Detection at the ASCO Annual Meeting 2024
YONGIN, South Korea, May 7, 2024 /PRNewswire/ -- GC Genome Corporation, a leading diagnostics company, today announced that it will present the new clinical data of its AI-based liquid biopsy platform on colorectal cancer detection at the 2024 American Society of Clinical Oncology (ASCO) Annual ...
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC)as Monotherapy for Advanced Gastric Cancer
SAN FRANCISCO and SUZHOU, China, May 7, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ...
HTL Biotechnology, market leader in biopolymers, acquires the Modern Meadow's human recombinant collagen platform for beauty and biomedical applications
JAVENÉ, France, May 6, 2024 /PRNewswire/ -- HTL Biotechnology strengthens its position as a global leader in the production and development of pharmaceutical-grade biopolymers by acquiring the beauty and biomedical division of American company Modern Meadow (Nutley, NJ). Notably, this acquisitio...
ThinkCyte Launches New Website and Showcases VisionSortTM at Global Events
TOKYO, May 7, 2024 /PRNewswire/ -- ThinkCyte today announced that it will be presenting at three major international scientific conferences in the first week of May and the launch of itsupdated website. The company will have a presence at the American Society for Immunology (AAI) fromMay 3rd to 7...
21st.BIO unveils a new pilot plant facility to accelerate impact of biotech innovations globally
* Combining world-class industrially proven technology with fermentation capacity, 21st.BIO helps customers get to scale faster, in a risk-mitigated and cost-effective way. * Margrethe Vestager, Executive Vice President of the European Commission, was onsite to inaugurate the pilot facility, ...
Alphamab Oncology to Present Chinese Clinical Data of JSKN003 for the Treatment of HER2-expressing Solid Tumors for the First Time at the 2024 ASCO Annual Meeting
SUZHOU, China, May 6, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that data from the clinical study conducted inChina (JSKN003-102) of anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 for the treatment of HER2-expressing advanced solid tumors, will be presente...
HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease
* HanAll has initiated a Phase III VELOS-4 study to evaluate the efficacy and safety of tanfanercept in dry eye based on the findings from the previous Phase III VELOS-3 study. * Tanfanercept demonstrated statistically significant improvement on the secondary outcome measure, Schirmer testing...
Bio Basic Asia Pacific Offers Free Re-Sequencing and Gel Analysis for Sanger Sequencing Services
SINGAPORE, May 2, 2024 /PRNewswire/ -- Bio Basic Asia Pacific
Clarivate Enhances Cortellis CMC Intelligence with Post-Approval Module to Accelerate Regulatory Success
Enhancements enable pharma, biotech and generics companies to streamline regulatory tracking and optimize life cycle management for small molecules and biologics LONDON, May 2, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announ...
Integrated cancer biotech Infinitopes secures £12.8m seed financing to enhance its Precision Immunomics™ antigen discovery technologies to target five more cancers
Funding also supports the start of phase I/IIa study for lead vaccine, ITOP1 OXFORD, England, May 2, 2024 /PRNewswire/ -- Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimula...
Neogen® Petrifilm® Celebrates 40 Years!
LANSING, Mich., May 1, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) is celebrating 40 years of Petrifilm, the innovation that changed how microbiologists around the world perform indicator testing. "In the food safety industry, Petrifilm is recognized as a true game-changer," saidJohn...
ArisGlobal Helps Boehringer Ingelheim Transform Safety Signal Processing by Leveraging Latest LifeSphere Solutions
LifeSphere Clarity drives efficiencies and reinvents the way Boehringer Ingelheim's pharmaceutical operations approach safety signals BOSTON, May 1, 2024 /PRNewswire/ -- ArisGlobal, a market leader in Life Sciences technology and the creator of LifeSphere®, announced today that research-driven g...
Shineco Develops Revolutionary New Product with Varied Applications to Positively Impact the Health Care Industry
BEIJING, May 1, 2024 /PRNewswire/ -- Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today that its subsidiaries Fuzhou Medashan Biotechnology Co., Ltd. and Kaifeng Yixi Biotechnology Co., Ltd. have innov...
Integrated cancer biotech Infinitopes secures £12.8m seed financing to enhance its Precision Immunomics™ antigen discovery technologies to target five more cancers
Funding also supports the start of phase I/IIa study for lead vaccine, ITOP1 OXFORD, England, May 1, 2024 /PRNewswire/ -- Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimula...
Eluminex Biosciences Announces FDA Acceptance of Investigational New Drug (IND) Application for EB-105 - A Novel Trispecific Fusion Antibody for Diabetic Macular Edema (DME) - and Upcoming Scientific Presentations
SAN FRANCISCO and SUZHOU, China, April 30, 2024 /PRNewswire/ -- Eluminex Biosciences (Eluminex), a privately-held biotechnology company focused on the development of advanced protein therapeutics for vision-threatening diseases and dermal facial aesthetics announced the acceptance of their EB-105...
National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma
SHENZHEN, China, April 30, 2024 /PRNewswire/ -- Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) announced that the company's lead innovative product Chidamide (Epidaza®) , an oral subtype-selective histone deacetylase (HDAC) inhibitor, combined with R-C...
A Potential First-In-Class Drug: CDE Approved Single-Arm Pivotal Clinical Study of LBL-024, An Anti-PD-L1/4-1BB Bispecific Antibody Developed by Leads Biolabs
NANJING, China, April 30, 2024 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-024, an anti-PD-L1/4-1BB bispecific antibody independently developed by Leads Biolabs with global intellectual property rights has received approval to co...
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
* The expanded partnership will allow Alnylam and Medison to help accelerate access for patients in multiple regions under one global alliance * Medison, the creator and leader of the multi-regional partnership category, will utilize its unique, unifiedplatform for efficient global commerciali...
HanAll Biopharma Reports Q1 2024 Financial Results and Provides Business Update
* Delivered solid performance to start 2024, with record-breaking first quarter revenue of34.1 billion KRW. Strong sales momentum continued from key products, funding investments in ongoing R&D programs. * Phase 3 VELOS-4 study of tanfanercept in dry eye disease expected to be initiated in th...
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00